Additionally, elevated expression of POPDC3 was significantly associated with adverse clinical outcomes (P < 0.05, Fig. 7I, J) and poorer survival of NSCLC patients (P < 0.05, Fig. 7K, L). The gene discussed is POPDC3; the disease is non-small cell lung carcinoma.